SH-SY5Y is a twice-subcloned cell line derived from the SK-N-SH neuroblastoma cell line. It serves as a model for neurodegenerative disorders since the cells can be converted to various types of functional neurons by the addition of specific compounds. In addition, the SH-SY5Y cell line has been used widely in experimental neurological studies, including analysis of neuronal differentiation, metabolism, and function related to neurodegenerative processes, neurotoxicity, and neuroprotection.
This cell line was derived from the SH-SY subclone of the parental SK-N-SH human neuroblastoma cell line. The parental SK-N-SH cell line was established in 1970 from metastatic cells found in the bone marrow aspirate of a four-year-old female of unknown ethnicity.
- June L. Biedler, PhD, former Chairman, Cell Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering
- Barbara A. Spengler, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
Ross RA et al. (1983) Coordinate morphological and biochemical interconversion of human neuroblastoma cells. Journal of the National Cancer Institute 71: 741-748 (PubMed ID: 6137586)
This cell line may be licensed nonexclusively for research or commercial purposes.
For internal research purposes by a commercial entity: Utilize MSK’s Express License, available here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.
To proceed, please download this contract, fill in all relevant fields, and email a scanned version to Alexandra Buga at email@example.com. Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.
For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, firstname.lastname@example.org.